MARKET INSIGHTS
Global Microcrystalline Cellulose as Pharmaceutical Excipient market size was valued at USD 721.5 million in 2024. The market is projected to grow from USD 772.4 million in 2025 to USD 1.30 billion by 2032, exhibiting a CAGR of 7.3% during the forecast period.
Microcrystalline cellulose (MCC) is a versatile pharmaceutical excipient derived from wood pulp or refined cotton, widely used as a binder, diluent, and disintegrant in solid dosage formulations. This purified, partially depolymerized cellulose is valued for its excellent compressibility, flow properties, and inert chemical nature, making it suitable for tablets, capsules, and other drug delivery systems.
Growth is fueled by expanding pharmaceutical production, rising demand for generic drugs, and technological advancements in excipient manufacturing. The nutraceutical sector’s expansion and a shift toward plant‑based excipients further broaden market reach. Key players such as DuPont, JRS Pharma, and Roquette are investing in capacity expansions and specialized MCC grades to support diverse formulation needs. The Asia‑Pacific region displays pronounced growth potential, driven by strengthening manufacturing capabilities in India and China.
Top 10 Companies in the Global Microcrystalline Cellulose Market (2026)
1. DuPont
Headquarters: Wilmington, Delaware, USA
Key Offering: High‑purity MCC grades for tablets, capsules, and advanced dosage forms
DuPont leverages its integrated pulp‑processing capabilities to deliver MCC with consistent particle size distribution and low moisture content, essential for high‑performance solid dosage products. The company’s recent investment in a new nanocellulose facility aims to meet the rising demand for excipients in biopharmaceuticals and 3‑D printed drug delivery systems.
Sustainability & Growth Initiatives: DuPont’s “Green MCC” program focuses on renewable sourcing and energy‑efficient manufacturing, targeting a 15% reduction in carbon intensity by 2030.
- Advanced milling technology for uniform particle morphology
- Strategic partnerships with leading CDMOs for rapid market deployment
- Continuous process validation to maintain GMP compliance
- Investment in research for MCC derivatives as peptide stabilizers
2. Roquette
Headquarters: L’Arbresle, France
Key Offering: Wood‑pulp and cotton‑based MCC for oral and topical applications
Roquette’s extensive upstream supply chain and proprietary purification processes enable the delivery of MCC with exceptional flow properties, supporting high‑speed tablet presses and ODT formulations. The company recently announced a joint venture in India to expand local production and reduce import dependence.
Sustainability & Growth Initiatives: Roquette’s “Circular MCC” initiative recycles cellulose waste streams, contributing to a 20% reduction in raw material footprint.
- Robust quality assurance system aligned with USP, EP, and JP monographs
- Dedicated R&D hub for high‑purity grades tailored to biologics
- Strategic alliances with regional pharmaceutical manufacturers
- Investment in digital traceability for supply chain transparency
3. Asahi Kasei
Headquarters: Tokyo, Japan
Key Offering: Premium MCC for high‑potency APIs and controlled‑release tablets
Asahi Kasei’s vertically integrated production ensures strict control over moisture content and particle size, critical for high‑potency formulations. The company is expanding its research into MCC‑based carriers for protein therapeutics.
Sustainability & Growth Initiatives: Asahi Kasei’s “Eco‑MCC” program targets zero‑waste manufacturing by 2035 through advanced recycling and renewable energy use.
- High‑purity cotton‑derived MCC for sensitive APIs
- Collaboration with academic institutions for formulation innovation
- Continuous improvement of milling efficiency
- Investment in green solvent technologies for cellulose extraction
4. JRS Pharma
Headquarters: Tokyo, Japan
Key Offering: Specialized MCC grades for nutraceuticals and ODTs
JRS Pharma focuses on niche markets, delivering MCC with tailored disintegration profiles for nutraceutical capsules and rapidly disintegrating tablets. The firm is scaling production in Asia to meet growing demand for plant‑based excipients.
Sustainability & Growth Initiatives: JRS Pharma’s “Renewable MCC” strategy emphasizes sourcing from sustainably managed forests and reducing water usage in processing.
- Customized MCC formulations for high‑dose tablets
- Partnerships with CDMOs to accelerate product launch
- Investment in 3‑D printing compatibility studies
- Digital platform for real‑time quality monitoring
5. Accent Microcell
Headquarters: Shanghai, China
Key Offering: Wood‑pulp MCC for large‑scale generic manufacturing
Accent Microcell has rapidly expanded its capacity in China, positioning itself as a key supplier for domestic generic drug producers. The company’s focus on cost‑effective production without compromising quality has attracted significant market share in Asia.
Sustainability & Growth Initiatives: Accent Microcell’s “Green Production” plan reduces energy consumption by 18% through process optimization.
- High‑yield pulp milling technology
- Strategic alliances with local pharma firms
- Compliance with international GMP standards
- Investment in automation for quality control
6. Sigachi
Headquarters: Tokyo, Japan
Key Offering: Cotton‑derived MCC for controlled‑release dosage forms
Sigachi specializes in MCC grades that enhance release profiles for extended‑release tablets. The company’s research pipeline includes MCC derivatives for peptide stabilization.
Sustainability & Growth Initiatives: Sigachi’s “Clean MCC” initiative targets zero‑emission processing lines by 2030.
- Advanced particle size control for release engineering
- Collaboration with universities for formulation research
- Investment in renewable energy for production
- Digital traceability of raw material sourcing
7. Wei Ming Pharmaceutical
Headquarters: Shanghai, China
Key Offering: High‑purity MCC for biologics and specialty drugs
Wei Ming Pharmaceutical focuses on MCC grades that support the stability of biologic APIs. The company is expanding its manufacturing footprint to serve emerging markets in Southeast Asia.
Sustainability & Growth Initiatives: Wei Ming’s “Sustainable MCC” program reduces water usage by 22% through closed‑loop systems.
- High‑purity cotton MCC for biologic formulations
- Partnerships with global CDMOs
- Investment in research for MCC as a protein carrier
- Energy‑efficient milling technology
8. Anhui Sunhere Pharmaceutical
Headquarters: Hefei, China
Key Offering: Wood‑pulp MCC for large‑volume generic production
Anhui Sunhere Pharmaceutical delivers MCC with consistent flow properties, enabling efficient high‑speed tablet manufacturing. The firm is investing in automation to support rapid scaling.
Sustainability & Growth Initiatives: Anhui Sunhere’s “Eco‑MCC” strategy targets a 25% reduction in carbon footprint by 2035.
- Robust pulp milling for uniform particle size
- Strategic partnerships with domestic manufacturers
- Continuous process validation for GMP compliance
- Automation of quality control processes
9. Rutocel
Headquarters: Woburn, Massachusetts, USA
Key Offering: Specialized MCC for ODTs and nutraceuticals
Rutocel’s niche focus on rapidly disintegrating formulations positions it as a preferred supplier for ODT and nutraceutical markets. The company is scaling production to meet growing demand in North America.
Sustainability & Growth Initiatives: Rutocel’s “Green MCC” program emphasizes low‑energy milling and renewable raw materials.
- High‑purity cotton MCC for ODTs
- Partnerships with CDMOs for accelerated market entry
- Investment in digital quality assurance
- Energy‑efficient processing lines
10. Shandong Guangda
Headquarters: Shandong, China
Key Offering: Wood‑pulp MCC for generic and specialty drugs
Shandong Guangda provides MCC with excellent compressibility, supporting high‑speed tablet presses for generic manufacturers. The company is expanding its capacity to serve both domestic and export markets.
Sustainability & Growth Initiatives: Shandong Guangda’s “Eco‑MCC” program focuses on reducing water consumption and waste generation.
- Consistent particle size distribution for tablet production
- Strategic alliances with local pharma firms
- Investment in automation for quality control
- Renewable energy use in production facilities
Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/283391/global-microcrystalline-cellulose-as-pharmaceutical-excipient-market
Get Full Report: https://www.24chemicalresearch.com/reports/283391/global-microcrystalline-cellulose-as-pharmaceutical-excipient-market
Outlook
Global Microcrystalline Cellulose as Pharmaceutical Excipient Market is projected to reach USD 1.30 billion by 2032, driven by escalating pharmaceutical production and a shift toward plant‑based excipients. The Asia‑Pacific region will maintain a leading position, while North America is expected to experience the fastest growth due to advanced drug delivery initiatives and stringent quality standards. Companies that can deliver high‑purity MCC with sustainable manufacturing practices will capture the most value.
Future Trends
- Expansion of MCC applications into 3‑D printed dosage forms and ODTs, requiring precise rheological control.
- Development of MCC derivatives capable of stabilizing peptides and proteins, opening new markets in biologics.
- Increased focus on green manufacturing, with companies adopting renewable energy and closed‑loop water systems.
- Strategic partnerships between global excipient suppliers and regional pharmaceutical manufacturers to accelerate product launch.
- Enhanced digital traceability and real‑time quality monitoring to meet evolving regulatory expectations.
- Top 10 Companies in the Powerful Paint Stripper Market (2026): Market Leaders Driving Global Industry - October 23, 2026
- Top 10 Companies in the Oligosaccharide Market (2026): Market Leaders Driving Functional Nutrition - October 23, 2026
- Top 10 Companies in the Southeast Asia 3,4,5‑Trihydroxybenzoic Acid (Gallic Acid) Market (2026): Market Leaders Driving Regional Innovation - October 23, 2026